Search icon
TCS, HDFCBANK, SBI Liquid Fund (G)
Medicamen Organics Ltd.

MEDIORG

Equity

NSE

Min. Investment

32,000.00

Open a free Demat account and invest in IPOs easily.

Download Orca

Google PlayApp Store

To access realtime data for GP Eco Solutions India Ltd. and use advance features for Applying IPO. Register or Login to Orca.

IPO Details

Bidding Dates

21 Jun 24 - 25 Jun 24

Price Range ₹

32 - 34

Total Equity

10.54Cr

Lot Size

4000

Exchange Status

NSE

IPO Doc

Subscription Rate

Non-Institutional Investor

0.00×

Qualified Institutional Buyers

0.00×

Employees

0.00×

Retail Investors

0.00×

Total subscription Rate

0.00×

IPO Timeline

Offer start

21 Jun 2024

Offer end

25 Jun 2024

Allotment

26 Jun 2024

Refund initiation

27 Jun 2024

Demat transfer

27 Jun 2024

Listing

28 Jun 2024

About Company

Incorporated in 1995, Medicamen Organics Limited develops, manufactures, and distributes pharmaceutical dosages, including generic tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. They serve both government (state and central) and private entities as a contract or third-party manufacturer. The company's product portfolio includes 84 items, offering a wide range of drugs such as antibacterials, antidiarrheals, antifungals, antimalarials, antidiabetics, proton pump inhibitors, antihistamines, antihypertensives, lipid preparations, antiparasitics, multivitamins, multiminerals, and non-steroidal anti-inflammatory drugs (NSAIDs). Medicamen Organics markets its products across India and internationally in countries like Congo, Benin, Kameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Burundi, Kyrgyzstan, and Kenya through third-party distributors. The company operates two WHO-GMP-approved manufacturing facilities in Haridwar, Uttarakhand, spanning 21,536 square feet. As of September 30, 2023, Medicamen Organics has entered into contract manufacturing agreements with 38 domestic partners and 12 merchant exporters.

Year Founded

15-03-1995

Promotor Details

Bal Kishan Gupta

Promoter Holdings Details

ParticularPre-IPOPost-IPO
Percentage81.2359.69
Share Capital69839006983900

Offer to Public

31,00,000.00 Cr

Project Details

  • Funding of expenses proposed to be incurred towards Product registration in the international market - 30cr
  • Plant updation and increase in production capacity - 22.5cr
  • Funding working capital requirements of our Company - 40cr

Objectives

  • Funding of expenses proposed to be incurred towards Product registration in the international markets
  • Plant updation and increase in production capacity
  • Funding working capital requirements of our Company
  • General Corporate Purposes.

Highlights

  • Medicamen Organics holds ISO 9001:2015 certification for quality management systems.
  • As of September 30, 2023, the company markets 84 products globally under various brand names.
  • The company holds product manufacturing approvals in numerous international markets, including countries like Congo, the Philippines, and Kenya.
  • Its manufacturing facilities in Ranipur, Haridwar, have "WHO" GMP approval.
  • Medicamen Organics has a strong presence in India and overseas markets.

Challenges

  • The company relies heavily on a few customers, with the top 10 customers accounting for a significant portion of total sales in recent years.
  • A significant portion of the company's purchases comes from its top 10 suppliers, making it vulnerable to supplier-related disruptions.
  • As of September 30, 2023, the company had outstanding secured loans worth Rs 5.84 crore, which could negatively impact its financial stability if not serviced properly.
  • The company’s directors and promoters are involved in several legal proceedings, including 10 criminal cases and 15 tax-related cases, which could adversely affect the business if judgments are unfavorable.
  • Any decline in product quality, increased competition, or shifts in demand could negatively impact the company’s business operations.

Financials

YearsTotal AssetsShare CapitalProfit After TaxConsolidated Net ProfitAdjusted EPS
20222,707.21600.009.239.230.1538
20233,211.98600.0095.7895.781.5963
20212,634.37600.0029.8129.810.4968
Enrich money logo